Review
Endocrinology & Metabolism
William F. Simonds
Summary: Cushing's syndrome can occur spontaneously or in the context of familial disease. Multiple endocrine neoplasia type 1 (MEN1) is unique among familial endocrine tumor syndromes as it can result in hypercortisolism due to pituitary, adrenal, or thymic neuroendocrine tumors. The clinical manifestations of MEN1 include primary hyperparathyroidism, pituitary tumors, gastroenteropancreatic neuroendocrine tumors, and bronchial carcinoid tumors. CS in MEN1 can be caused by ACTH-secreting pituitary tumors, adrenocortical neoplasms, or ectopic tumoral ACTH secretion from thymic neuroendocrine tumors.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Isabella Santiago de Melo Miranda, Luciana Pinto Valadares, Gustavo Barcelos Barra, Pedro Goes Mesquita, Lidiana Bandeira de Santana, Lucas Faria de Castro, Ticiane Henriques Santa Rita, Luciana Ansaneli Naves
Summary: This study conducted a retrospective analysis of 500 medical records from the Neuroendocrinology Outpatient Clinic of the University Hospital of Brasilia, and identified 4 families with MEN1 syndrome. Variants in the MEN1 gene were found in all 11 patients from these families. The findings contribute to the understanding of genetic and phenotypic characteristics of MEN1 patients in Brasilia.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Endocrinology & Metabolism
Elisabetta Lavezzi, Alessandro Brunetti, Valeria Smiroldo, Gennaro Nappo, Vittorio Pedicini, Eleonora Vitali, Giampaolo Trivellin, Gherardo Mazziotti, Andrea Lania
Summary: This article presents two cases of MEN4 and provides some indications for the management of these patients through a review of the current literature. According to the literature, hyperparathyroidism is the most common clinical feature of MEN4, followed by pituitary adenoma and neuroendocrine tumors. However, MEN4 appears to be a variant of MEN with milder clinical features and later onset.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Kuan-Yu Lin, Yu-Ting Kuo, Mei-Fang Cheng, Pei-Lung Chen, Hsiu-Po Wang, Tsu-Yao Cheng, Chia-Hsuin Chang, Hsiang-Fong Kao, Shih-Hung Yang, Hung-Yuan Li, Chia-Hung Lin, Yuh-Tsyr Chou, An-Ko Chung, Wan-Chen Wu, Jin-Ying Lu, Chih-Yuan Wang, Wen-Hui Hsih, Chen-Yu Wen, Wei-Shiung Yang, Shyang-Rong Shih
Summary: Recent studies suggest that the clinical characteristics and biological behavior of pituitary tumors in patients with MEN1 may be less aggressive than previously reported. Increased imaging of the pituitary as recommended by screening guidelines identifies more tumors potentially at an earlier stage. However, it is unknown if these tumors have different clinical characteristics in different MEN1 mutations.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Abdallah Al-Salameh, Guillaume Cadiot, Alain Calender, Pierre Goudet, Philippe Chanson
Summary: Multiple endocrine neoplasia type 1 (MEN1) is a rare syndrome characterized by the co-occurrence of primary hyperparathyroidism, duodenopancreatic neuroendocrine tumours (NETs) and/or pituitary adenomas. Patients with MEN1 should undergo tailored biochemical and imaging screening. Knowledge about the clinical phenotype of these tumours has progressed over the past 10 years, particularly in France and the Netherlands.
NATURE REVIEWS ENDOCRINOLOGY
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Arafat Ali, Jonathan Revels, David T. Wang, Lily L. Wang, Sherry S. Wang
Summary: Having a thorough understanding of the spectrum of tumors associated with MEN gene mutations can assist in screening, diagnostic workup, and post-treatment monitoring of patients with MEN-related gene mutations.
AMERICAN JOURNAL OF ROENTGENOLOGY
(2021)
Article
Pathology
Anna Vera D. Verschuur, Aranxa S. M. Kok, Folkert H. M. Morsink, Wendy W. J. de Leng, Medard F. M. van den Broek, Marco J. Koudijs, Johan A. Offerhaus, Gerlof D. Valk, Menno R. Vriens, Bernadette P. M. van Nesselrooij, Wenzel M. Hackeng, Lodewijk A. A. Brosens
Summary: A clinical diagnosis of multiple endocrine neoplasia type 1 (MEN1) syndrome is usually confirmed with genetic testing in the germline. This study investigated the potential of menin immunohistochemistry in parathyroid adenomas as an additional tool in the recognition and genetic diagnosis of MEN1 syndrome. Menin loss was found in 100% of patients with MEN1 and 9% of patients without MEN1, indicating the usefulness of menin immunohistochemistry in identifying MEN1-related tumors. It also showed high positive and negative predictive values for the diagnosis of MEN1.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2023)
Article
Oncology
Grigoris Effraimidis, Ulrich Knigge, Maria Rossing, Peter Oturai, Ase Krogh Rasmussen, Ulla Feldt-Rasmussen
Summary: Neuroendocrine neoplasms (NENs) are rare tumors that have shown a significant increase in incidence over the past four decades. These tumors arise from neuroendocrine cells and have diverse presentations and behaviors, depending on the organ involved. Multiple endocrine neoplasia type 1 (MEN-1) is a key genetic syndrome associated with NENs and research on diagnosis and treatment is progressing.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Endocrinology & Metabolism
Aurore Geslot, Magaly Vialon, Philippe Caron, Solange Grunenwald, Delphine Vezzosi
Summary: MEN1 gene mutation leads to various endocrine and non-endocrine tumors, with significant therapeutic progress made in the management of parathyroid, pancreatic, and pituitary impairments. Early monitoring and regular assessment are essential for optimal treatment and prevention of tumor progression. Trust-building between patients and healthcare providers is crucial for long-term support and continuity of care.
ANNALES D ENDOCRINOLOGIE
(2021)
Article
Genetics & Heredity
Antongiulio Faggiano, Beatrice Fazzalari, Nevena Mikovic, Flaminia Russo, Virginia Zamponi, Rossella Mazzilli, Vito Guarnieri, Maria Piane, Vincenzo Visco, Simona Petrucci
Summary: The aim of this study was to evaluate the predictive role of specific clinical factors for the diagnosis of MEN1 and MEN4 in patients with an initial diagnosis of gastrointestinal, bronchial, or thymic neuroendocrine tumor (NET). The preliminary data showed that a diagnosis of NET in patients with a negative family history may suggest MEN1 in the presence of >= three positive phenotypic criteria.
Article
Medicine, General & Internal
Carolina Chaves, Tiago Nunes da Silva, Bernardo Dias Pereira, Joao Anselmo, Isabel Claro, Branca M. Cavaco, Ana Saramago, Valeriano Leite
Summary: MEN1 is a familial syndrome caused by disruption of the MENIN tumor suppressor protein, leading to challenges in management due to its effects on various endocrine tissues and predisposition to tumors. This case presented a patient with multiple endocrine and autoimmune disorders, underwent surgical interventions and long-term familial genetic screening, resulting in stable outcomes during a 24-year follow-up period. The interplay between MENIN and the immune system highlighted in this case may have implications for future targeted surveillance and treatment of MEN1 patients.
Review
Endocrinology & Metabolism
Antonio Bianchi, Sabrina Chiloiro, Antonella Giampietro, Simona Gaudino, Rosalinda Calandrelli, Ciro Mazzarella, Carmelo Caldarella, Mario Rigante, Marco Gessi, Liverana Lauretti, Laura De Marinis, Alessandro Olivi, Alfredo Pontecorvi, Francesco Doglietto
Summary: Growth hormone-secreting adenomas exhibit a wide range of behaviors and outcomes, from mild disease to aggressive neoplasms. Treatment for patients who do not respond to surgery or first-generation somatostatin receptor ligands may involve multiple surgical, medical, and radiation treatments. Currently, there are no markers that can predict the prognosis or aggressiveness of acromegaly. A multidisciplinary approach is necessary to tailor treatment for difficult/aggressive cases, including radiation therapy, chemotherapy, and emerging treatments.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Amanda J. Seabrook, Jessica E. Harris, Sofia B. Velosa, Edward Kim, Aideen M. McInerney-Leo, Trisha Dwight, Jason Hockings, Nicholas G. Hockings, Judy Kirk, Paul J. Leo, Amanda J. Love, Catherine Luxford, Mhairi Marshall, Ozgur Mete, David J. Pennisi, Matthew A. Brown, Anthony J. Gill, Gregory Hockings, Roderick J. Clifton-Bligh, Emma L. Duncan
Summary: Pathogenic germline MAX variants are associated with multiple tumors including pheochromocytoma, ganglioneuroma, neuroblastoma, and pituitary neuroendocrine tumors. Clinical, genetic, immunohistochemical, and functional studies on affected families confirmed the associations. Immunohistochemistry and functional studies provided additional evidence for the roles of MAX variants in tumor development.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Carolina R. C. Pieterman, Gerlof D. Valk
Summary: This review provides an overview of novel insights in the clinical management of patients with Multiple Endocrine Neoplasia Type 1. The review focuses on the last decade and discusses updates in diagnosis, primary hyperparathyroidism, duodenopancreatic neuroendocrine tumours (NETs), thymus NETs, lung NETs, pituitary adenomas, and breast cancer in MEN1 syndrome. The review also mentions the impact of MEN1 on quality of life and the financial burden associated with the condition. Furthermore, the review highlights the need for further studies to define predictors of tumour behaviour and effects of more individualized interventions.
CLINICAL ENDOCRINOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Francesca Marini, Francesca Giusti, Francesco Tonelli, Maria Luisa Brandi
Summary: Pancreatic neuroendocrine tumors (pNETs) are a rare group of cancers, accounting for about 1-2% of all pancreatic neoplasms, with some arising in patients with endocrine tumor syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1). MEN1-related pNETs present challenges in treatment due to their unique characteristics and the need for extensive surgery. Epigenetic-based therapies aiming to correct DNA methylation and histone modifications may offer a potential therapeutic strategy for MEN1 pNETs resistant to standard treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Endocrinology & Metabolism
Zihao Wang, Xiaopeng Guo, Wenze Wang, Lu Gao, Xinjie Bao, Ming Feng, Wei Lian, Huijuan Zhu, Bing Xing
Summary: The study systematically investigated lipidomic and transcriptomic alterations associated with invasiveness in SCAs, and constructed a lipidomic signature to predict invasive SCAs, providing potential therapeutic targets for SCAs.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Zihao Wang, Xiaopeng Guo, Lu Gao, Yu Wang, Yi Guo, Bing Xing, Wenbin Ma
Summary: Pediatric gliomas were classified into three immune subtypes based on immunological profiling, with immune hot tumors having favorable prognosis and better response to immunotherapies, while immune cold tumors had dismal prognosis and poor immunotherapy responsiveness. Immune subtypes were also correlated with somatic mutations, copy number alterations, and molecular pathways related to tumorigenesis, metabolism, and immune responses.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Endocrinology & Metabolism
Fengzhou Du, Qiao Chen, Xiaojun Wang, Xiaopeng Guo, Zihao Wang, Lu Gao, Xiao Long, Bing Xing
Summary: This study found that acromegaly patients experienced significant soft tissue improvements in the nose and lip regions after surgical treatment. Two years post-surgery, there were significant reductions in nasal width, tip protrusion, face curve length, and vermilion area. The change in nasal width was associated with decreases in GH and IGF-1 levels.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Hanze Du, Danning Wu, Xiang Zhou, Hongbo Yang, Huijuan Zhu, Shi Chen, Hui Pan
Summary: The relationship between maternal thyroid function and pregnancy outcomes is still controversial in women planning pregnancy. This study found that preconception TSH levels were associated with preterm delivery, large for gestational age (LGA), and low birth weight (LBW). The safe range of TSH for preconception women was within 0.91 to 1.82 mIU/L.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Computer Science, Information Systems
Yunying Feng, Siyu Liang, Yuelun Zhang, Shi Chen, Qing Wang, Tianze Huang, Feng Sun, Xiaoqing Liu, Huijuan Zhu, Hui Pan
Summary: This study investigates the application and accuracy of artificial intelligence methods for automated medical literature screening. The results show that recall is more important than specificity or precision in literature screening, and a recall over 0.95 should be prioritized. Manual literature screening is still indispensable for medical systematic reviews.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
(2022)
Review
Endocrinology & Metabolism
Da Zhang, Lin Lu, Hui-Juan Zhu, Yu Xiao, Xian-Lin Han, Shun-Da Du, Hua-Dan Xue, Qing-Xing Liu, Zhao-Hui Zhu, Ming-Ming Hu, Xiao Zhai, Xiao-Ping Xing, Zhao-Lin Lu
Summary: SSA treatment leads to clinical and biochemical improvement with a good safety profile in patients with EAS-p-NETs. However, only a few patients experience tumor progression inhibition from SSA treatment. Combined with other treatments, SSAs may improve the prognosis of patients with EAS-p-NETs.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Xu-dong Bao, Lin Lu, Hui-juan Zhu, Yong Yao, Ming Feng, Ren-zhi Wang, Xiao Zhai, Yong Fu, Feng-ying Gong, Zhao-lin Lu
Summary: This study presents a rare case of pediatric giant pituitary ACTH adenoma, and identifies unusual concurrent mutations that may contribute to its early onset and large volume.
BMC ENDOCRINE DISORDERS
(2022)
Review
Oncology
Xiaopeng Guo, Xin Yang, Jiaming Wu, Huiyu Yang, Yilin Li, Junlin Li, Qianshu Liu, Chen Wu, Hao Xing, Penghao Liu, Yu Wang, Chunhua Hu, Wenbin Ma
Summary: Glioblastoma (GBM) is a common malignant primary brain tumor with a low 5-year survival rate. Tumor-treating fields (TTFields) have emerged as the fourth most effective treatment option for GBMs, prolonging patient survival and showing acceptable adverse events. TTFields disrupts cell mitosis, delays DNA repair, enhances autophagy, inhibits cell metabolism and angiogenesis, and limits cancer cell migration. It also strengthens antitumor immunity, increases cell membrane and blood-brain barrier permeability, and disrupts DNA-damage-repair processes. However, the overall acceptance of TTFields in clinical practice is still low. This review provides an updated understanding of the mechanism of action, efficacy, safety, clinical concerns, and future perspectives of TTFields in GBMs.
Letter
Cardiac & Cardiovascular Systems
Shi Chen, Jiaqi Qiang, Ran Tian, Tao Yuan, Mei Li, Yuxiu Li, Huijuan Zhu, Yan Tang, Bin Zhao, Hui Pan
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Letter
Biochemistry & Molecular Biology
Huijuan Xu, Haiyang Hao, Shirui Wang, Xueru Liu, Wen Lyu, Zhentao Zuo, Yan Zhuo, Jidong Mi, Yong Q. Zhang, Rui Tian, Huijuan Zhu
JOURNAL OF GENETICS AND GENOMICS
(2023)
Article
Endocrinology & Metabolism
Jie Liu, Yamei Yang, Lian Duan, Xiaofeng Chai, Huijuan Zhu, Kan Deng, Xiaolan Lian, Yong Yao
Summary: This study found that the octreotide suppression test can be used as an efficient tool to predict the decline of thyroid-stimulating hormone in patients with thyrotrophin-secreting pituitary adenomas. The 24-hour and 72-hour timepoints were particularly effective in guiding the use of somatostatin analogs.
CLINICAL ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Hongbo Yang, Meiping Chen, Yujie Wang, Lingjuan Jiang, Linjie Wang, Lian Duan, Fengying Gong, Huijuan Zhu, Hui Pan
Summary: Metabolomics analysis revealed distinct metabolic patterns between AGHD patients and healthy controls, involving various metabolic pathways. rhGH treatment altered the levels of specific glycerophospholipid compounds and fatty acid ester compounds in serum, which were significantly correlated with clinical parameters. The metabolomic profiles of AGHD patients are important for assessing the efficacy of rhGH treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Linjie Wang, Xiaoxue Chen, Xiaoyan Liu, Hui Miao, Fengying Gong, Hongbo Yang, Lian Duan, Huijuan Zhu, Wei Sun
Summary: This study systematically investigates the metabolomics of cerebrospinal fluid (CSF) in different pituitary stalk lesions. CSF metabolomics is a useful strategy for biomarker discovery.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Meiping Chen, Lian Duan, Hui Miao, Na Yu, Shengmin Yang, Linjie Wang, Fengying Gong, Yong Yao, Huijuan Zhu
Summary: This study analyzed the clinical characteristics and treatment outcomes of acromegalic patients with giant growth hormone-secreting pituitary adenomas (GHPAs). The results showed that patients with giant GHPAs had more frequent visual impairment and gonadal axis dysfunction compared to patients with macro GHPAs. As the size of the adenoma increased, the total resection rate decreased and postoperative complications and multimodal treatment strategies increased significantly. However, with aggressive multimodal therapy, the biochemical remission rate of patients with giant GHPAs was comparable to that of patients with macro adenoma, though postoperative complications and hypopituitarism need close monitoring.